Goldman Sachs
TRIB

Goldman Sachs’s Trinity Biotech TRIB Stock Holding History

Goldman Sachs’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-73
Closed -$32K – 6515
2021
Q2 		$32K Buy
+73
New +$36.4K ﹤0.01% 6117
2021
Q1 		– Sell
-152
Closed -$87K – 6357
2020
Q4 		$87K Buy
+152
New +$75.5K ﹤0.01% 5315
2020
Q3 		– Sell
-396
Closed -$130K – 5540
2020
Q2 		$130K Buy
+396
New +$90.5K ﹤0.01% 4922
2017
Q2 		– Sell
-286
Closed -$256K – 6973
2017
Q1 		$256K Sell
286
-8
-3% -$7.5K ﹤0.01% 5572
2016
Q4 		$305K Buy
+294
New +$304K ﹤0.01% 5471

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's TRIB Position: Q3 2021 in Review

Goldman Sachs sold out of Trinity Biotech (TRIB) in Q3 2021, closing a stake of 73 shares — an estimated $32K sold.

Goldman Sachs first reported a position in TRIB in Q4 2016 and held it in 5 quarters. The position peaked at $305K in Q4 2016. 21 funds tracked by Wall St. Rank hold TRIB as of Q3 2021.

  • Goldman Sachs reported no remaining Trinity Biotech position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 73 Trinity Biotech shares in Q3 2021, an estimated $32K.
  • Goldman Sachs first reported a position in Trinity Biotech in Q4 2016 and held it in 5 quarters.
  • Goldman Sachs's Trinity Biotech position peaked at $305K in Q4 2016.
  • 21 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.